Short Interest in Annexon, Inc. (NASDAQ:ANNX) Rises By 26.1%

Annexon, Inc. (NASDAQ:ANNX) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 8,690,000 shares, a growth of 26.1% from the September 15th total of 6,890,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is presently 6.6 days.

Annexon Price Performance

Shares of ANNX opened at $7.38 on Friday. The business’s 50-day moving average is $6.17 and its 200-day moving average is $5.65. The company has a market capitalization of $779.70 million, a price-to-earnings ratio of -6.00 and a beta of 1.28. Annexon has a fifty-two week low of $1.57 and a fifty-two week high of $8.40.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). Equities research analysts expect that Annexon will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on ANNX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Monday, September 9th. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Insider Transactions at Annexon

In other Annexon news, EVP Ted Yednock sold 5,500 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the transaction, the executive vice president now owns 10,000 shares of the company’s stock, valued at approximately $56,400. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 17,388 shares of company stock valued at $107,072 in the last quarter. Insiders own 12.67% of the company’s stock.

Hedge Funds Weigh In On Annexon

A number of hedge funds have recently modified their holdings of ANNX. Creative Planning grew its stake in shares of Annexon by 29.5% in the 3rd quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after buying an additional 7,914 shares in the last quarter. Park Avenue Securities LLC lifted its stake in Annexon by 136.2% in the third quarter. Park Avenue Securities LLC now owns 118,068 shares of the company’s stock valued at $699,000 after acquiring an additional 68,082 shares during the last quarter. SG Americas Securities LLC grew its position in Annexon by 117.8% in the third quarter. SG Americas Securities LLC now owns 32,763 shares of the company’s stock worth $194,000 after acquiring an additional 17,723 shares in the last quarter. Maven Securities LTD acquired a new position in shares of Annexon during the 2nd quarter worth $170,000. Finally, Susquehanna Fundamental Investments LLC raised its holdings in shares of Annexon by 385.6% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 163,025 shares of the company’s stock valued at $799,000 after purchasing an additional 129,455 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.